Gene expression profiling of the response of esophageal carcinoma cells to cisplatin

被引：11

作者：

Takashima, N. ^{[1
]}

Ishiguro, H. ^{[1
]}

Kuwabara, Y. ^{[1
]}

Kimura, M. ^{[1
]}

Mitui, A. ^{[1
]}

Mori, Y. ^{[1
]}

Mori, R. ^{[1
]}

Tomoda, K. ^{[1
]}

Hamaguchi, M. ^{[1
]}

Ogawa, R. ^{[1
]}

Katada, T. ^{[1
]}

Harada, K. ^{[1
]}

Fujii, Y. ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci Oncol Immunol & Surg, Mizuho Ku, Nagoya, Aichi 4678601, Japan

来源：

DISEASES OF THE ESOPHAGUS | 2008年 / 21卷 / 03期

关键词：

cisplatin; esophageal cancer; microarray;

D O I：

10.1111/j.1442-2050.2007.00761.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Cisplatin is the most common chemotherapeutic agent used in esophageal cancer. However, sensitivity to cisplatin varies greatly between patients. It is important to identify the gene(s) that are related to the sensitivity to cisplatin in esophageal cancer patients. The IC50 for cisplatin was measured for 15 esophageal cancer cell lines (TE1-5, TE8-15, KYSE140, and KYSE150). RNA was extracted from each of these cell lines and a normal esophageal epithelial cell line, namely, Het1A, and gene expression profiles were analyzed using an oligonucleotide microarray consisting of 34 594 genes. TE4 was highly resistant and TE12, 14, and 15 were sensitive to cisplatin. Thirty-seven genes were differentially expressed in the cisplatin-resistant esophageal cancer cell line. Our investigation provides a list of candidate genes that may be associated with resistance to cisplatin in esophageal cancer cells, which may serve as a basis for additional functional studies.

引用

页码：230 / 235

页数：6

共 26 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2] Thrombospondin-1 expression in epithelial ovarian carcinoma:: Association with p53 status, tumor angiogenesis, and survival in platinum-treated patients [J].

Alvarez, AA ;

Axelrod, JR ;

Whitaker, RS ;

Isner, PD ;

Bentley, RC ;

Dodge, RK ;

Rodriguez, GC .

GYNECOLOGIC ONCOLOGY, 2001, 82 (02) :273-278

[3] Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase [J].

Banerjee, D ;

Mayer-Kuckuk, P ;

Capiaux, G ;

Budak-Alpdogan, T ;

Gorlick, R ;

Bertino, JR .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1587 (2-3) :164-173

[4] Molecular aspects of resistance to antitumor platinum drugs [J].

Brabec, V ;

Kasparkova, J .

DRUG RESISTANCE UPDATES, 2002, 5 (3-4) :147-161

[5]

Dan S, 2002, CANCER RES, V62, P1139

[6]

DeRisi J, 1996, NAT GENET, V14, P457

[7] Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring [J].

Golub, TR ;

Slonim, DK ;

Tamayo, P ;

Huard, C ;

Gaasenbeek, M ;

Mesirov, JP ;

Coller, H ;

Loh, ML ;

Downing, JR ;

Caligiuri, MA ;

Bloomfield, CD ;

Lander, ES .

SCIENCE, 1999, 286 (5439) :531-537

[8] Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines [J].

Holford, J ;

Beale, PJ ;

Boxall, FE ;

Sharp, SY ;

Kelland, LR .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (15) :1984-1990

[9]

Hu YC, 2001, CLIN CANCER RES, V7, P2213

[10]

Husain A, 1998, CANCER RES, V58, P1120

← 1 2 3 →